Variations in Etiology of Ventilator-associated Pneumonia across Four Treatment Sites
- 1 August 1999
- journal article
- research article
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 160 (2) , 608-613
- https://doi.org/10.1164/ajrccm.160.2.9812034
Abstract
This retrospective multicenter study compared microorganisms documented by quantitative cultures from bronchoscopic samples in episodes of ventilator-associated pneumonia (VAP) from three different institutions in Barcelona (B), Montevideo (M), and Seville (S). The observations were compared with the findings reported by Trouillet and coworkers (AJRCCM 1998;157:531-539) in Paris (P). The objective was to evaluate whether a classification of etiologies of VAP in four groups, based on the number of ventilation days and previous antimicrobial use, might contribute to establishing generalized guidelines for empirical therapy. Significant variations in etiologies (p < 0.05) were found in all of the microorganisms isolated from VAP episodes across three treatment sites when compared with the reference site (P). In Group 1 (< 7 d and absence of antibiotics), Pseudomonas aeruginosa remained extremely infrequent (3 of 89, 3.3%) in the joint category, whereas the incidence of Acinetobacter baumannii was significantly higher, owing to M findings. On the other hand, one site (B) had a significantly lower incidence of multiresistant pathogens (Methicillin-resistant Staphylococcus aureus [MRSA] and nonfermenters other than P. aeruginosa), even in Group 2 (< 7 d and antibiotics), Group 3 (>/= 7 d and absence of antibiotics), and Group 4 (antibiotics and >/= 7 days). Similar findings were documented when episodes were grouped according to Groups 1 and 3 of the ATS guidelines. We conclude that causes of VAP varied markedly across four treatment sites, resulting in the need for large-scale variations in antimicrobial prescribing practices. Instead of following general recommendations, antimicrobial prescribing practices for VAP should be based on up-to-date information of the pattern of multiresistant isolates from each institution.Keywords
This publication has 19 references indexed in Scilit:
- Ventilator-associated Pneumonia Caused by Potentially Drug-resistant BacteriaAmerican Journal of Respiratory and Critical Care Medicine, 1998
- Risk Factors for Infection by Acinetobacter baumannii in Intubated Patients With Nosocomial PneumoniaChest, 1997
- The Value of Routine Microbial Investigation in Ventilator-Associated PneumoniaAmerican Journal of Respiratory and Critical Care Medicine, 1997
- Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. A consensus statement, American Thoracic Society, November 1995.American Journal of Respiratory and Critical Care Medicine, 1996
- Continuous Aspiration of Subglottic Secretions in Preventing Ventilator-Associated PneumoniaAnnals of Internal Medicine, 1995
- Risk Factors forStaphylococcus aureusNosocomial Pneumonia in Critically III PatientsAmerican Review of Respiratory Disease, 1990
- Incidence, Risk, and Prognosis Factors of Nosocomial Pneumonia in Mechanically Ventilated PatientsAmerican Review of Respiratory Disease, 1990
- Nosocomial PneumoniaChest, 1988
- Statement on Standards for the Diagnosis and Care of Patients with Chronic Obstructive Pulmonary Disease (COPD) and AsthmaAmerican Review of Respiratory Disease, 1987
- APACHE IICritical Care Medicine, 1985